Victoria Socha

DocwireNews

Hepatorenal syndrome type 1 (HRS-1), a severe renal complication of decompensated cirrhosis, is treated with the FDA-approved vasopressin analogue terlipressin. A full response for the management of acute kidney injury (AKI) is described in guidelines from the International Club of Ascites as a serum creatinine at the end of treatment within 0.3 mg/dL of baseline. Baseline may be within 3 months prior to admission or, if unavailable, upon admission.According to Muhammad A. Mujtaba, MD, and colleagues, there may also be a clinical benefit associated with a partial response, defined as AKI regression and a reduction in serum creatinine of &ge;0.3 mg/dL above baseline. Because a historic baseline is not always available, the researchers conducted a pooled data analysis to examine the clinical impact of a relative response, defined as a &gt;30% reduction in serum creatinine from the start of treatment to the end of treatment, regardless of the historic baseline and HRS reversal status, in patients with HRS-1 who were treated with terlipressin.Results of the analysis were reported during a poster session at the NKF Spring Clinical Meetings 2023 in a poster titled A Reduction in Serum Creatinine of a Least 30% Leads to Meaningful Outcomes in Patients With Hepatorenal Syndrome Type 1: A Pooled Analysis of 3 Phase III Studies.The analysis included pooled data from three phase 3 placebo-controlled studies (OT-0401, REVERSE, and CONFIRM) to evaluate the relative response to terlipressin versus placebo in patients with HRS-1. The need for renal replacement therapy (RRT) and the number of patients alive at day 90 were compared based on the relative response in the pooled intent-to-treat population. Statistical significance was determined using Chi-square tests.The pooled intent-to-treat population included a total of 608 patients; of those, 352 were in the terlipressin group and 256 were in the placebo group. More patients in the terlipressin group achieved a relative response compared with the placebo group (43% [n=151] vs 23% [n=60], respectively; P&lt;.001).By day 90, in the pooled population, there were associations between a relative response and a lower incidence of RRT (15%, n=32/211) compared with no response (45%, n=1277/397). Seventy-one percent of patients with a relative response (n=150/211) were alive at day 90 compared with 42% (n=165/397) of those with&nbsp; no response.In conclusion, the researchers said, &ldquo;A &gt;30% reduction in serum creatinine from the start of treatment to the end of treatment with terlipressin is a clinically meaningful end point that is associated with a lower incidence of RRT and a higher number of patients alive at day 90.&rdquo;Source: Mujtaba MA, Zafar Z, Jamil K. A reduction in serum creatinine of at least 30% leads to meaningful clinical outcomes in patients with hepatorenal syndrome type 1: a pooled analysis of 3 phase III studies. Poster #20. Abstract of a poster presented at the National Kidney Foundation Spring Clinical Meetings 2023; April 11-15, 2023; Austin, Texas.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Terlipressin to Treat Patients With Hepatorenal Syndrome Type 1

Acute Kidney Injury

Analysis of pooled data from three phase 3 placebo-controlled studies to evaluate the relative response to terlipressin versus placebo in patients with HRS-1.

Outcomes in patients with hepatorenal syndrome

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe